In vivo quantification of human serotonin 1A receptor using 11C-CUMI-101, an agonist PET radiotracer

Journal of Nuclear Medicine

Volumn 51, Issue 12, 2010, Pages 1892-1900

  Milak, Matthew S ^a,b   DeLorenzo, Christine ^a   Zanderigo, Francesca ^b   Prabhakaran, Jaya ^a   Kumar, J S Dileep ^a,b   Majo, Vattoly J ^a   Mann, J John ^a   Parsey, Ramin V ^a,b  

^a Columbia University College of Physicians and Surgeons ^*  (United States)

^b NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

Author keywords

Bootstrap; Compartment; Kinetic; Test retest reproducibility; Voxel

Indexed keywords

2 [4 [4 (2 METHOXYPHENYL)PIPERAZIN 1 YL)BUTYL] 4 METHYL] 1,2,4 TRIAZINE 3,5 DIONE O METHYL C 11; DRUG METABOLITE; SEROTONIN 1A AGONIST; SEROTONIN 1A RECEPTOR; TRACER; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BINDING AFFINITY; BLOOD BRAIN BARRIER; BRAIN REGION; DISSOCIATION CONSTANT; DRUG PENETRATION; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; EQUILIBRIUM CONSTANT; FEMALE; HUMAN; HUMAN EXPERIMENT; IN VIVO STUDY; MALE; NORMAL HUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REPRODUCIBILITY; TEST RETEST RELIABILITY;

ADULT; BLOOD-BRAIN BARRIER; BRAIN; FEMALE; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; KINETICS; MAGNETIC RESONANCE IMAGING; MALE; MODELS, STATISTICAL; PIPERAZINES; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RECEPTOR, SEROTONIN, 5-HT1A; REPRODUCIBILITY OF RESULTS; SEROTONIN RECEPTOR AGONISTS; TRIAZINES;

EID: 78651314014     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.110.076257     Document Type: Article

References (36)

1. Kasper S, Tauscher J, Willeit M, et al. Receptor and transporter imaging studies in schizophrenia, depression, bulimia and Tourette's disorder: implications for psychopharmacology. World J Biol Psychiatry. 2002;3:133-146.
2. Jolas T, Schreiber R, Laporte AM, et al. Are postsynaptic 5-HT1A receptors involved in the anxiolytic effects of 5-HT1A receptor agonists and in their inhibitory effects on the firing of serotonergic neurons in the rat? J Pharmacol Exp Ther. 1995;272:920-929.
3. Arango V, Underwood MD, Boldrini M, et al. Serotonin 1A receptors, serotonin transporter binding and serotonin transporter mRNA expression in the brainstem of depressed suicide victims. Neuropsychopharmacology. 2001;25:892-903.
4. Stanley M, Mann JJ. Increased serotonin-2 binding sites in frontal cortex of suicide victims. Lancet. 1983;1:214-216.
5. Parsey RV, Olvet DM, Oquendo MA, Huang YY, Ogden RT, Mann JJ. Higher 5-HT1A receptor binding potential during a major depressive episode predicts poor treatment response: preliminary data from a naturalistic study. Neuropsychopharmacology. 2006;31:1745-1749.
6. Parsey RV, Oquendo MA, Ogden RT, et al. Altered serotonin 1A binding in major depression: a [carbonyl-C-11]WAY100635 positron emission tomography study. Biol Psychiatry. 2006;59:106-113.
7. Mann JJ, McBride PA, Brown RP, et al. Relationship between central and peripheral serotonin indexes in depressed and suicidal psychiatric inpatients. Arch Gen Psychiatry. 1992;49:442-446.
8. Placidi GP, Oquendo MA, Malone KM, Huang YY, Ellis SP, Mann JJ. Aggressivity, suicide attempts, and depression: relationship to cerebrospinal fluid monoamine metabolite levels. Biol Psychiatry. 2001;50:783-791.
9. Cheney BV, Lahti RA, Barsuhn C. Drug affinities for the agonist and antagonist states of the opioid receptor. Eur J Pharmacol. 1982;77:259-263.
10. De Lean A, Stadel JM, Lefkowitz RJ. A ternary complex model explains the agonist-specific binding properties of the adenylate cyclase-coupled beta-adrenergic receptor. J Biol Chem. 1980;255:7108-7117. (Pubitemid 11232874)
11. Bantick RA, Rabiner EA, Hirani E, de Vries MH, Hume SP, Grasby PM. Occupancy of agonist drugs at the 5-HT1A receptor. Neuropsychopharmacology. 2004;29:847-859. (Pubitemid 38528764)
12. 11C]- raclopride. Synapse. 2004;52:188-208.
13. 11C]2-(4-(4-(2-methoxyphenyl) piperazin-1-yl)butyl)-4-methyl-1,2,4- triazi ne-3,5(2H,4H)dione in nonhuman primates. Eur J Nucl Med Mol Imaging. 2007;34:1050-1060.
14. 11C-CUMI-101, an agonist radiotracer for imaging serotonin 1A receptor in vivo with PET. J Nucl Med. 2008;49:587-596.
15. 11C]PE2I and positron emission tomography. J Cereb Blood Flow Metab. 2009;29:1332-1345.
16. 11C]DASB and positron emission tomography in humans: modeling considerations. J Cereb Blood Flow Metab. 2007;27:205-217.
17. Parsey RV, Slifstein M, Hwang DR, et al. Validation and reproducibility of measurement of 5-HT1A receptor parameters with [carbonyl-11C]WAY-100635 in humans: comparison of arterial and reference tissue input functions. J Cereb Blood Flow Metab. 2000;20:1111-1133.
18. Gunn RN, Sargent PA, Bench CJ, et al. Tracer kinetic modeling of the 5-HT1A receptor ligand [carbonyl-11C]WAY- 100635 for PET. Neuroimage. 1998;8:426-440.
19. DeLorenzo C, Klein A, Mikhno A, et al. A new method for assessing PET-MRI coregistration. Proceedings of the SPIE. 2009;7258:72592W-7-72592W-8.
20. Duvernoy H. The Human Brain: Surface, Three-dimensional Sectional Anatomy and MRI. New York, NY: Springer-Verlag Wien; 1991.
21. Talairach J, Tournoux P. Co-Planar Stereotactic Atlas of the Human Brain: Three-Dimensional Proportional System - An Approach of Cerebral Imaging. New York, NY: Theime Medical Publisher; 1988.
22. Kates WR, Abrams MT, Kaufmann WE, Breiter SN, Reiss AL. Reliability and validity of MRI measurement of the amygdala and hippocampus in children with fragile X syndrome. Psychiatry Res Neuroimaging. 1997;75:31-48.
23. Killiany RJ, Moss MB, Nicholson T, Jolesz F, Sandor T. An interactive procedure for extracting features of the brain from magnetic resonance images: the lobes. Hum Brain Mapp. 1997;5:355-363.
24. Ardekani BA, Guckemus S, Bachman A, Hoptman MJ, Wojtaszek M, Nierenberg J. Quantitative comparison of algorithms for inter-subject registration of 3D volumetric brain MRI scans. J Neurosci Methods. 2005;142:67-76.
25. Klein A, Andersson J, Ardekani BA, et al. Evaluation of 14 nonlinear deformation algorithms applied to human brain MRI registration. Neuroimage. 2009;46:786-802.
26. 11C]McN 5652. Biol Psychiatry. 2003;54:1414-1421.
27. Parsey RV, Ogden RT, Mann JJ. Determination of volume of distribution using likelihood estimation in graphical analysis: elimination of estimation bias. J Cereb Blood Flow Metab. 2003;23:1471-1478.
28. Ogden RT. Estimation of kinetic parameters in graphical analysis of PET imaging data. Stat Med. 2003;22:3557-3568.
29. 11C-methyl]-(-)-cocaine PET studies in human subjects. J Cereb Blood Flow Metab. 1990;10:740-747.
30. Lammertsma AA, Hume SP. Simplified reference tissue model for PET receptor studies. Neuroimage. 1996;4:153-158.
31. Zanderigo F, Ogden RT, Bertoldo A, Cobelli C, Mann JJ, Parsey RV. Empirical Bayesian estimation in graphical analysis: a voxel-based approach for the determination of the volume of distribution in PET studies. Nucl Med Biol. 2010;37:443-451.
32. Slifstein M, Laruelle M. Effects of statistical noise on graphic analysis of PET neuroreceptor studies. J Nucl Med. 2000;41:2083-2088.
33. 11C]PE2I: quantitative modeling and test-retest reproducibility. J Cereb Blood Flow Metab. 2008;28:1059-1069.
34. Parsey RV, Ogden RT, Miller JM, et al. Higher serotonin 1A binding in a second major depression cohort: modeling and reference region considerations. Biol Psychiatry. 2010;68:170-178.
35. Milak MS, Kumar JSD, Severance AJ, et al. Altered binding in baboons of [C-11]CUMI-101, a 5-HT1A agonist PET tracer, in response to intravenous citalopram. Neuroimage. 2008;41:T162-T162.
36. Parsey RV, Oquendo MA, Simpson NR, et al. Effects of sex, age, and aggressive traits in man on brain serotonin 5-HT1A receptor binding potential measured by PET using [C-11]WAY-100635. Brain Res. 2002;954:173-182.